Dilantin and Omniscan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Dilantin (phenytoin sodium) and Omniscan (gadodiamide). Common drug interactions include oedema among females and nephrogenic systemic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Dilantin and Omniscan. It is created by eHealthMe based on reports of 51 people who take the same drugs from the FDA, and is updated regularly.

What is Dilantin?

Dilantin has active ingredients of phenytoin sodium. It is often used in epilepsy. eHealthMe is studying from 20,858 Dilantin users. Check the latest studies of Dilantin.

What is Omniscan?

Omniscan has active ingredients of gadodiamide. eHealthMe is studying from 6,169 Omniscan users. Check the latest studies of Omniscan.



On Jul, 04, 2026

51 people who take Dilantin and Omniscan together, and have interactions are studied.

Dilantin and Omniscan drug interactions.

What are the common drug interactions of Dilantin and Omniscan, by gender? *:

female:

  1. Oedema (fluid collection in tissue)
  2. Bone pain
  3. Stress
  4. Finger deformity (a deformed position of the finger)
  5. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  6. Emotional distress
  7. Pain of skin
  8. Muscle spasticity (tight or stiff muscles and an inability to control those muscles)
  9. Abasia (inability to walk)
  10. Abdominal pain

male:

  1. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  2. Pain
  3. Heart rate decreased
  4. Heart rate increased
  5. Heart rate irregular
  6. Injury
  7. Lower respiratory tract infection
  8. Nasopharyngitis (inflammation of the nasopharynx)
  9. Skin fibrosis (fibrous tissue formation on skin)
  10. Wheezing (a high-pitched whistling sound made while you breath)

What are the common drug interactions of Dilantin and Omniscan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Abdominal pain
  2. Asthenia (weakness)
  3. Cellulitis (infection under the skin)
  4. Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
  5. Dyspnoea (difficult or laboured respiration)
  6. Klebsiella sepsis (klebsiella causes a potentially fatal whole-body inflammation)
  7. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  8. Pneumonia
  9. Pulmonary alveolar haemorrhage (acute bleeding)
  10. Pyrexia (fever)

30-39:

  1. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  2. Joint range of motion decreased (disease of joint movement)
  3. Oedema peripheral (superficial swelling)
  4. Pain
  5. Joint contracture (a permanent shortening of a muscle or joint)
  6. Skin hypertrophy (skin cells enlarges)
  7. Skin tightness
  8. Anxiety
  9. Skin induration (an abnormally hard spot or area on the skin)
  10. Pain in extremity

40-49:

  1. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  2. Oedema peripheral (superficial swelling)
  3. Mobility decreased (ability to move is reduced)
  4. Pain
  5. Skin induration (an abnormally hard spot or area on the skin)
  6. Joint range of motion decreased (disease of joint movement)
  7. Skin fibrosis (fibrous tissue formation on skin)
  8. Skin hypertrophy (skin cells enlarges)
  9. Skin tightness
  10. General physical health deterioration (weak health status)

50-59:

  1. Rash papular (redness with papule)
  2. Skin atrophy (wasting of skin)
  3. Skin ulcer
  4. Peau d'orange (orange peel skin)
  5. Renal impairment (severely reduced kidney function)
  6. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  7. Pain
  8. Skin induration (an abnormally hard spot or area on the skin)
  9. Skin hypertrophy (skin cells enlarges)
  10. Skin tightness

60+:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Pain
  4. Pain of skin
  5. Peau d'orange (orange peel skin)
  6. Pruritus (severe itching of the skin)
  7. Scar
  8. Skin hypertrophy (skin cells enlarges)
  9. Skin lesion
  10. Skin tightness

What are the existing conditions these people have? *

  1. Nuclear Magnetic Resonance Imaging Brain: 36 people, 70.59%
  2. Pain: 16 people, 31.37%
  3. Nuclear Magnetic Resonance Imaging Abdominal: 8 people, 15.69%
  4. Haemorrhage Intracranial (bleeding within the skull): 8 people, 15.69%
  5. Weakness: 6 people, 11.76%
  6. Headache (pain in head): 6 people, 11.76%
  7. Stress And Anxiety: 5 people, 9.80%
  8. Back Pain: 5 people, 9.80%
  9. High Blood Pressure: 5 people, 9.80%
  10. Multiple Myeloma (cancer of the plasma cells): 5 people, 9.80%

* Approximation only. Some reports may have incomplete information.

Do you take Dilantin and Omniscan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Dilantin and Omniscan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Dilantin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Omniscan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Dilantin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Omniscan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on phenytoin sodium and gadodiamide (the active ingredients of Dilantin and Omniscan, respectively), and Dilantin and Omniscan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: